| Name | Oxford Nanopore Technologies |
|---|---|
| Epic | ONT |
| Isin | GB00BP6S8Z30 |
| Index | UK250 UK350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 137.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £1,320.38 | Debt ratio | n/a |
| Shares in issue | 963.78 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -25.55 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -16 | 52-week high / low | 91.30p / 219.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Oxford Nanopore Technologies |
|---|---|
| Address | Gosling Building, Edmund Halley Road, Oxford Science Park, Oxford, United Kingdom, OX4 4DQ |
| Telephone | +44 (0)845 034 7900 |
| Website | http://nanoporetech.com/ |
| Director | Position |
|---|---|
| Dr Gurdial (Gordon) Sanghera | CEO |
| Mr Nick Keher | CFO |
| Mr Heather Preston | Non-Executive Director |
| Ms Kate Priestman | Non-Executive Director |
| Mr Adrian Nevil Hennah | Non-Executive Director |
| Dr Daniel Mahony | Non-Executive Director |
| Mr John O'Higgins | Non-Executive Director |
| Mr Sarah Fortune | Non-Executive Director |
| Mr Duncan Tatton-Brown | Non-Executive Chairman |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/12/24 | 31/12/23 | 31/12/22 |
| Intangible asssets and goodwill | 43.81 | 32.91 | 30.04 |
| Investments and other non-current assets | n/a | 0.74 | 0.83 |
| Total non-current assets | 221.96 | 329.88 | 185.89 |
| Inventory / work in progress | 99.45 | 101.55 | 87.7 |
| Trade and other receivables | 62.71 | 61.47 | 62.9 |
| Cash and equivalents | 199.52 | 220.54 | 356.78 |
| Other current assets and asset held for resale | 158.42 | 63.62 | 130.62 |
| Total of all assets | 742.05 | 777.06 | 823.89 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 111.49 | 89.2 | 91.54 |
| Long term liabilities | 44.22 | 44.01 | 38.8 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 155.71 | 133.21 | 130.33 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 586.34 | 643.85 | 693.56 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 0.1 | 0.09 | 0.08 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -401.96 | -257.71 | -105.99 |
| Share premium account | 779.7 | 698.55 | 627.56 |
| Total equity | 586.34 | 643.85 | 693.56 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -152.33 | -168.61 | -98.48 |
| Pre-tax profit | -139.96 | -149.77 | -83.41 |